World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
120
Citations
70729
World Ranking
3682
National Ranking
2026

Overview

Christopher J. Logothetis is affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their research primarily focuses on fields related to Medicine, with significant contributions to Biochemistry, Genetics and Molecular Biology. Within these fields, their work spans subfields such as Pulmonary and Respiratory Medicine, Oncology, Cancer Research, Molecular Biology, and Radiology, Nuclear Medicine and Imaging.

The main topics explored in their research include Prostate Cancer Treatment and Research, Prostate Cancer Diagnosis and Treatment, Cancer, Lipids, and Metabolism, Radiopharmaceutical Chemistry and Applications, Bone health and treatments, Bladder and Urothelial Cancer Treatments, and Cancer Immunotherapy and Biomarkers.

Christopher J. Logothetis has published extensively in several leading scientific venues. Frequent publication venues include:

  • Journal of Clinical Oncology
  • bioRxiv (Cold Spring Harbor Laboratory)
  • Cancer Research
  • European Urology
  • Clinical Cancer Research

Notable recent papers authored or co-authored by Logothetis include:

  • Assessment of Luminal and Basal Phenotypes in Bladder Cancer, 2020, Scientific Reports
  • Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors, 2020, European Urology
  • Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy, 2022, Nature
  • Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022, 2022, European Urology
  • The MD Anderson Prostate Cancer Patient-derived Xenograft Series (MDA PCa PDX) Captures the Molecular Landscape of Prostate Cancer and Facilitates Marker-driven Therapy Development, 2020, Clinical Cancer Research

The scientist frequently collaborates with others in their field. Their frequent co-authors include:

  • Paul G. Corn
  • Ana M. Aparicio
  • Sumit K. Subudhi
  • Patricia Troncoso
  • Eleni Efstathiou

Best Publications

  • Abiraterone and Increased Survival in Metastatic Prostate Cancer

    Johann S. de Bono;Christopher J. Logothetis;Arturo Molina;Karim Fizazi

  • The Immune Landscape of Cancer

    Vésteinn Thorsson;David L Gibbs;Scott D Brown;Denise Wolf

  • Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy

    Charles J. Ryan;Matthew R. Smith;Johann S. De Bono;Arturo Molina

  • Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial

    Eugene D. Kwon;Charles G. Drake;Howard I. Scher;Karim Fizazi

  • Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3

    Howard I. Scher;Michael J. Morris;Walter M. Stadler;Celestia Higano

  • Prostate cancer. Clinical practice guidelines in oncology.

    James Mohler;Robert R. Bahnson;Barry Boston;J. Erik Busby

  • Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

    Karim Fizazi;Howard I. Scher;Arturo Molina;Christopher J. Logothetis

  • Genomic and Functional Approaches to Understanding Cancer Aneuploidy

    Alison M. Taylor;Alison M. Taylor;Juliann Shih;Gavin Ha;Gavin Ha;Galen F. Gao

  • Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study

    Charles J. Ryan;Matthew R. Smith;Karim Fizazi;Fred Saad

  • Glucocorticoid Receptor Confers Resistance to Antiandrogens by Bypassing Androgen Receptor Blockade

    Vivek K. Arora;Emily Schenkein;Rajmohan Murali;Sumit K. Subudhi

  • Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer

    Tomasz M. Beer;Eugene D. Kwon;Charles G. Drake;Karim Fizazi

  • Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci

    Fredrick R. Schumacher;Ali Amin Al Olama;Sonja I. Berndt;Sara Benlloch

  • Pathogenic Germline Variants in 10,389 Adult Cancers

    Kuan-Lin Huang;R Jay Mashl;Yige Wu;Deborah I Ritter

  • Steps toward mapping the human vasculature by phage display

    Wadih Arap;Mikhail G. Kolonin;Martin Trepel;Johanna Lahdenranta

  • A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors.

    Christopher J. Logothetis;Francisco H. Dexeus;Laury Finn;Avishay Sella

  • Personalized Oncology Through Integrative High-Throughput Sequencing: A Pilot Study

    Sameek Roychowdhury;Matthew K. Iyer;Dan R. Robinson;Robert J. Lonigro

  • CTLA-4 blockade increases IFNγ-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients

    Chrysoula I. Liakou;Ashish Kamat;Derek Ng Tang;Hong Chen

  • Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017

    Silke Gillessen;Gerhardt Attard;Tomasz M Beer;Himisha Beltran

  • VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer

    Jianjun Gao;John F. Ward;Curtis A. Pettaway;Lewis Zhichang Shi

  • Phase I Trial of the Proteasome Inhibitor Bortezomib in Patients With Advanced Solid Tumors With Observations in Androgen-Independent Prostate Cancer

    Christos N. Papandreou;Danai D. Daliani;Darrell Nix;Hong Yang

Frequent Co-Authors

Patricia Troncoso
Patricia Troncoso The University of Texas MD Anderson Cancer Center
Karim Fizazi
Karim Fizazi University of Paris-Saclay
Curtis A. Pettaway
Curtis A. Pettaway The University of Texas MD Anderson Cancer Center
Gary E. Gallick
Gary E. Gallick The University of Texas MD Anderson Cancer Center
Louis L. Pisters
Louis L. Pisters The University of Texas MD Anderson Cancer Center
Xuemei Wang
Xuemei Wang The University of Texas MD Anderson Cancer Center
Howard I. Scher
Howard I. Scher Memorial Sloan Kettering Cancer Center
Fred Saad
Fred Saad University of Montreal
Johann S. de Bono
Johann S. de Bono Institute of Cancer Research
David E. Neal
David E. Neal University of Cambridge

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine opens the door to numerous online degree programs and pathways, each catering to different backgrounds and goals. For registered nurses who want to advance their qualifications without stepping away from work, affordable rn to bsn programs are a popular choice, allowing RNs to earn their Bachelor of Science in Nursing conveniently and at a lower cost.

Those with a non-nursing bachelor's degree who are eager for a rapid entry into nursing may find direct entry msn online options particularly attractive. These programs let students accelerate toward becoming nurse practitioners or leaders without previous nursing credentials.

Accessibility also matters. Students looking for less competitive admissions can consider some of the easiest nursing programs to get into, which offer more flexible entry requirements, making a career in nursing more attainable for many.

Beyond nursing, allied health careers such as medical billing and coding provide essential opportunities. Students interested in flexible study options and financial support can explore the financial aid for medical billing and coding online classes, enabling a pathway into the healthcare industry without the need for clinical practice.

Best Scientists Citing Christopher J. Logothetis

Trending Scientists

Recently Published Articles